These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 34993841)

  • 1. Low-dose ranibizumab administration in retinopathy of prematurity.
    Tök L; Seyrek L; Yalçın Tök Ö
    Int Ophthalmol; 2022 May; 42(5):1545-1552. PubMed ID: 34993841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Intravitreal Ranibizumab in the Treatment of Retinopathy of Prematurity in Chinese Infants.
    Yi Z; Su Y; Zhou Y; Zheng H; Ye M; Xu Y; Chen C
    Curr Eye Res; 2016 Aug; 41(8):1092-1097. PubMed ID: 26580816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Favorable outcomes in the treatment of aggressive posterior retinopathy of prematurity.
    Sahinoglu-Keskek N; Akkoyun I; Torer B
    Eur J Ophthalmol; 2021 Jan; 31(1):179-183. PubMed ID: 31718282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriate dose of intravitreal ranibizumab for ROP: a retrospective study.
    Chen Y; Wang S; Chen S; Chen X; Han L; Zhong Q; Zhang K
    BMC Ophthalmol; 2022 Jun; 22(1):271. PubMed ID: 35729540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.
    Ells AL; Wesolosky JD; Ingram AD; Mitchell PC; Platt AS
    Can J Ophthalmol; 2017 Oct; 52(5):468-474. PubMed ID: 28985806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.
    Chan JJT; Lam CPS; Kwok MKM; Wong RLM; Lee GKY; Lau WWY; Yam JCS
    Sci Rep; 2016 Jun; 6():27082. PubMed ID: 27256987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vascularization process after intravitreal ranibizumab injections for aggressive posterior retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Arq Bras Oftalmol; 2017; 80(1):30-34. PubMed ID: 28380099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical study on intravitreous injection of ranibizumab for aggressive posterior retinopathy of prematurity].
    Tian R; Zhang G; Tang S; Guo J; Tan W
    Zhonghua Yan Ke Za Zhi; 2015 Nov; 51(11):822-5. PubMed ID: 26850583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.
    Baumal CR; Goldberg RA; Fein JG
    Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):432-8. PubMed ID: 25970863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3 with plus disease.
    Menke MN; Framme C; Nelle M; Berger MR; Sturm V; Wolf S
    BMC Ophthalmol; 2015 Mar; 15():20. PubMed ID: 25886603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of ultra-low-dose (0.1 mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: A case series.
    Ahmed IS; Hadi AM; Hassan HH
    Eur J Ophthalmol; 2020 Jan; 30(1):40-47. PubMed ID: 30428702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity.
    Sukgen EA; Koçluk Y
    Graefes Arch Clin Exp Ophthalmol; 2019 Jan; 257(1):49-55. PubMed ID: 30397793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of a biosimilar ranibizumab monotherapy for the treatment of retinopathy of prematurity.
    Prajapati V; Choudhary T; Chauhan W; Shah S; Handa R; Jahan B; Malviya S; Sengupta S
    Indian J Ophthalmol; 2023 Feb; 71(2):411-415. PubMed ID: 36727329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SHORT-TERM OUTCOMES AFTER INTRAVITREAL INJECTIONS OF CONBERCEPT VERSUS RANIBIZUMAB FOR THE TREATMENT OF RETINOPATHY OF PREMATURITY.
    Jin E; Yin H; Li X; Zhao M
    Retina; 2018 Aug; 38(8):1595-1604. PubMed ID: 28699927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined intravitreal ranibizumab and zone I sparing laser ablation in infants with posterior zone I retinopathy of prematurity.
    Parchand SM; Agrawal D; Gangwe A; Saraogi T; Agrawal D
    Indian J Ophthalmol; 2021 Aug; 69(8):2164-2170. PubMed ID: 34304202
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity.
    Aldebasi T; Guma MA; Bashir R; Al Saif S; Altwaijri WA; Al Bekairy AM
    Med Princ Pract; 2019; 28(6):526-532. PubMed ID: 30995663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of intravitreal ranibizumab treatment for retinopathy of prematurity in infants.
    Sukgen EA; Koçluk Y
    Cutan Ocul Toxicol; 2017 Dec; 36(4):356-361. PubMed ID: 28277877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the effectiveness of conbercept and ranibizumab treatment for retinopathy of prematurity.
    Cheng Y; Zhu X; Linghu D; Liang J
    Acta Ophthalmol; 2020 Dec; 98(8):e1004-e1008. PubMed ID: 32385940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.